Monofree (Tropicamide)

Tropicamide blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary muscles. By preventing parasympathetic stimulation, it stops the pupil from constricting and relaxes the ciliary body, resulting in pupil dilation and loss of accommodation needed for diagnostic and therapeutic eye work.

The specific dosing regimen for Monofree is determined by the prescribing ophthalmologist based on the intended examination or procedure. The prescriber selects the number of drops, concentration, and timing appropriate for each patient.

Safety data for tropicamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician after evaluating the individual situation.

To request Monofree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Tropicamide provides rapid onset and relatively short duration of mydriasis compared with agents like phenylephrine or cyclopentolate. This makes it suitable for routine diagnostic exams where a brief dilation is sufficient, while longer‑acting drugs may be preferred for procedures requiring extended pupil dilation.

Monofree should be stored at room temperature, away from direct sunlight. Keep the bottle tightly closed in its original packaging to protect it from moisture and light. Do not freeze the solution, and discard any product that appears discolored or contains particles.

Monofree is applied topically to the eye as a sterile ophthalmic solution. The prescriber typically instills one to two drops into the conjunctival sac of the target eye(s) using aseptic technique, usually several minutes before the examination or procedure.

Serious risks include allergic reactions, severe ocular inflammation, persistent mydriasis, and acute angle‑closure glaucoma in patients with narrow‑angle anatomy. Systemic anticholinergic effects such as dry mouth, rapid heart rate, or confusion may also occur, especially if large amounts are absorbed.

Monofree should be avoided in patients with known hypersensitivity to tropicamide or any formulation component, those with narrow‑angle or acute angle‑closure glaucoma, and individuals in whom pupil dilation could compromise vision or ocular health. The prescribing clinician must evaluate each case.